Resource Center

More to Explore - Information About Blood Cancers for Patients, Families and Healthcare Professionals

The Word:


January 29, 2013 - Myeloma - The Latest on Research and Treatment from the American Society of Hematology (ASH®) Annual Meeting

Your order contains  item(s)  View Order

Note: The free Adobe Acrobat Reader® is required to view and print Adobe PDF files, and the free Windows Media Player or RealPlayer is required to listen to the MP3 audio files.

Date: January 29, 2013
Time: 12:00 p.m. - 1:30 p.m. ET
Location: Telephone/Web
View: Program Slides
Read: Myeloma News | Transcript
Listen: Presentation | Q&A Session
Access: Virtual Lecture

Topics Covered

  • Updates about current and emerging myeloma treatment options
  • Updates in myeloma maintenance therapy
  • The role of clinical trials in the advancement of myeloma treatment
  • Advances in myeloma treatment side effects management


Kenneth C. Anderson, MD
Kraft Family Professor of Medicine
Department of Medicine
Harvard Medical School
Director, Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, MA

Questions Asked by the Myeloma Community 

  • Is there a new study about when treatment should begin for patients diagnosed with multiple myeloma in the smoldering stage?
  • If the level of the M-spike protein is not observable, does this indicate myeloma is in remission?
  • Do steroid medications and spinal injections affect bone marrow and blood work results for the M-protein?
  • What are the chances of pomalidomide (Pomalyst®) being tolerated, if thalidomide (Thalomid®) was not?
  • Please comment on T cell and T cell receptor therapy in myeloma. For example, Carl June at Penn. 
  • Is there a limit to the number of transplants that a patient can have? 
  • Please discuss maintenance therapy post-stem cell transplant, including when there is a complete response.
  • Is it beneficial to reinstate lenalidomide (Revlimid®) maintenance therapy that was started after transplant and was discontinued for fear of getting a secondary cancer? 
  • If taking lenalidomide (Revlimid®) 25 milligrams, as maintenance, can the dose be decreased? Or, is it safe to stay on this dose indefinitely? 
  • How do treatments for Myeloma change when the patient also has primary amyloidosis?
  • Is central nervous system neuropathy a side effect of bortezomib (Velcade®)?  If so, what remedies are effective?
  • What do you recommend for a patient with nerve pain following shingles and for preventing shingles in patients with myeloma?
  • Are there benefits of utilizing complementary therapies such as acupuncture to help with pain?
  • Please comment on the use of curcumin for smoldering myeloma.

Sponsors and Supporters

This program is sponsored by The Leukemia & Lymphoma Society and supported by grants from Celgene Corporation, Millennium: The Takeda Oncology Company, and Onyx Pharmaceuticals, Inc.

This program is not sponsored, sanctioned by, or part of the 54th Annual Meeting of the American Society of Hematology (ASH®)

last updated on Thursday, September 11, 2014

Get Information
& Support

Contact an Information Specialist.